| Title |
Cannabinoids for Neuropathic Pain
|
|---|---|
| Published in |
Current Pain and Headache Reports, August 2014
|
| DOI | 10.1007/s11916-014-0451-2 |
| Pubmed ID | |
| Authors |
Perry G. Fine, Mark J. Rosenfeld |
| Abstract |
Treatment options for neuropathic pain have limited efficacy and use is fraught with dose-limiting adverse effects. The endocannabinoid system has been elucidated over the last several years, demonstrating a significant interface with pain homeostasis. Exogenous cannabinoids have been demonstrated to be effective in a range of experimental neuropathic pain models, and there is mounting evidence for therapeutic use in human neuropathic pain conditions. This article reviews the history, pharmacologic development, clinical trials results, and the future potential of nonsmoked, orally bioavailable, nonpsychoactive cannabinoids in the management of neuropathic pain. |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 7 | 44% |
| Canada | 2 | 13% |
| Spain | 1 | 6% |
| Unknown | 6 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 88% |
| Practitioners (doctors, other healthcare professionals) | 2 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 94 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 20 | 21% |
| Researcher | 16 | 17% |
| Student > Master | 12 | 13% |
| Other | 10 | 10% |
| Student > Ph. D. Student | 7 | 7% |
| Other | 16 | 17% |
| Unknown | 15 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 28% |
| Agricultural and Biological Sciences | 12 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 11% |
| Psychology | 9 | 9% |
| Biochemistry, Genetics and Molecular Biology | 6 | 6% |
| Other | 16 | 17% |
| Unknown | 15 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 31. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2020.
All research outputs
#1,188,914
of 24,086,622 outputs
Outputs from Current Pain and Headache Reports
#47
of 826 outputs
Outputs of similar age
#12,438
of 240,815 outputs
Outputs of similar age from Current Pain and Headache Reports
#3
of 17 outputs
Altmetric has tracked 24,086,622 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 826 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 240,815 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.